FDA Priority Review for Syndax Leukemia Drug

Tuesday, 26 March 2024, 21:11

The FDA has granted Priority Review status for Syndax's market application for revumenib in treating KMT2Ar acute leukemia. This move accelerates the drug approval process, potentially benefiting patients awaiting new treatment options. The action date signifies a crucial milestone in the drug's regulatory journey.

https://store.livarava.com/f52c9891-ebb5-11ee-aec2-63fd8ea994ba.jpg — FDA Priority Review for Syndax Leukemia Drug

FDA Grants Priority Review for Syndax Leukemia Drug: Action Date Set

Syndax (SNDX) announced that the FDA has granted Priority Review status for its market application for revumenib in the treatment of KMT2Ar acute leukemia. The move marks an accelerated approval process for the drug, potentially offering new hope for patients.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.